Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Albert Labs International (FRA:VB50) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Albert Labs International's Enterprise Value for the quarter that ended in Sep. 2023 was €1.05 Mil.
Albert Labs International's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albert Labs International EV-to-EBIT Related Terms
Albert Labs International EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB50 vs VRTX, REGN, SGEN: EV-to-EBIT Comparison
For the Biotechnology subindustry, Albert Labs International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Albert Labs International EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Albert Labs International's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Albert Labs International's EV-to-EBIT falls into.
Albert Labs International's current Enterprise Value is €0.25 Mil.
Albert Labs International's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albert Labs International (FRA:VB50) has a EV-to-EBIT of 0.59 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Albert Labs International and its competitors.
Is Albert Labs International's EV-to-EBIT too high?
Albert Labs International's current EV-to-EBIT is 0.59. The Biotechnology industry median EV-to-EBIT is 12.78. Albert Labs International's value of 0.59 is 95.4% below this industry median.
How does Albert Labs International's EV-to-EBIT compare to VRTX and REGN?
Albert Labs International's EV-to-EBIT of 0.59 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 12.78. Albert Labs International's value of 0.59 is 95.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.78, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Albert Labs International's current EV-to-EBIT of 0.59 is 95.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Albert Labs International and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Albert Labs International's current EV-to-EBIT is 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert Labs International stock overvalued right now?
Albert Labs International (FRA:VB50) has a current EV-to-EBIT of 0.59. The current EV-to-EBIT is 0.59 and 95.4% below the Biotechnology industry median of 12.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Albert Labs International (FRA:VB50), the current EV-to-EBIT is 0.59 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Albert Labs International Corp is a laboratory-based, clinical research, and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of a clinical pathway.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB50 has been successfully added to your 
